Profitability ratios measure the company ability to generate profitable sales from its resources (assets).
Paying user area
Try for free
Danaher Corp. pages available for free this week:
- Balance Sheet: Assets
- Balance Sheet: Liabilities and Stockholders’ Equity
- Common-Size Income Statement
- Analysis of Reportable Segments
- Analysis of Geographic Areas
- Dividend Discount Model (DDM)
- Net Profit Margin since 2005
- Price to Earnings (P/E) since 2005
- Price to Sales (P/S) since 2005
- Analysis of Revenues
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Danaher Corp. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Profitability Ratios (Summary)
Based on: 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-01), 10-Q (reporting date: 2021-07-02), 10-Q (reporting date: 2021-04-02), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-10-02), 10-Q (reporting date: 2020-07-03), 10-Q (reporting date: 2020-04-03).
- Gross Profit Margin
- The gross profit margin exhibited a generally stable and slightly declining trend over the observed periods, starting from 55.98% in late 2020, peaking at around 60.95% in early 2022, and subsequently declining to approximately 59.66% by mid-2025. This indicates a modest contraction in the company's core profitability from sales over time, although the margin remained relatively high and consistent.
- Operating Profit Margin
- The operating profit margin showed a rising trend in the initial periods, increasing from 18.99% in late 2020 to a peak of 27.61% in late 2022. Following this peak, a steady decline occurred, dropping to 18.39% by mid-2025. This pattern suggests that the company experienced improvements in operational efficiency or cost management initially, but faced challenges or increased costs that reduced operating profitability in subsequent quarters.
- Net Profit Margin
- The net profit margin followed a similar trajectory to the operating margin, growing from 16.36% in late 2020 to peak at 23.32% in late 2022. Afterward, it showed a gradual decline to 14.21% by mid-2025. The margin's movement reflects the net effects of operating results combined with financing and tax considerations, indicating that profitability at the bottom line improved significantly before weakening over the later periods.
- Return on Equity (ROE)
- Return on equity increased steadily from 9.17% in late 2020 to a high of 14.4% by late 2022, evidencing enhanced value generation for shareholders during that time. From that peak, ROE decreased markedly to 6.52% by mid-2025, suggesting that the company's ability to generate profits from shareholders' equity diminished considerably in recent periods.
- Return on Assets (ROA)
- The return on assets followed an upward trend initially, growing from 4.79% in late 2020 to a maximum of 8.55% in late 2022. Subsequently, a decline was observed, reducing ROA to 4.18% by mid-2025. This indicates that the company's efficiency in utilizing its assets to generate earnings improved initially but weakened significantly thereafter.
Return on Sales
Return on Investment
Gross Profit Margin
Jun 27, 2025 | Mar 28, 2025 | Dec 31, 2024 | Sep 27, 2024 | Jun 28, 2024 | Mar 29, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jul 1, 2022 | Apr 1, 2022 | Dec 31, 2021 | Oct 1, 2021 | Jul 2, 2021 | Apr 2, 2021 | Dec 31, 2020 | Oct 2, 2020 | Jul 3, 2020 | Apr 3, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||
Gross profit | |||||||||||||||||||||||||||||
Sales | |||||||||||||||||||||||||||||
Profitability Ratio | |||||||||||||||||||||||||||||
Gross profit margin1 | |||||||||||||||||||||||||||||
Benchmarks | |||||||||||||||||||||||||||||
Gross Profit Margin, Competitors2 | |||||||||||||||||||||||||||||
AbbVie Inc. | |||||||||||||||||||||||||||||
Amgen Inc. | |||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | |||||||||||||||||||||||||||||
Eli Lilly & Co. | |||||||||||||||||||||||||||||
Gilead Sciences Inc. | |||||||||||||||||||||||||||||
Johnson & Johnson | |||||||||||||||||||||||||||||
Merck & Co. Inc. | |||||||||||||||||||||||||||||
Pfizer Inc. | |||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-01), 10-Q (reporting date: 2021-07-02), 10-Q (reporting date: 2021-04-02), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-10-02), 10-Q (reporting date: 2020-07-03), 10-Q (reporting date: 2020-04-03).
1 Q2 2025 Calculation
Gross profit margin = 100
× (Gross profitQ2 2025
+ Gross profitQ1 2025
+ Gross profitQ4 2024
+ Gross profitQ3 2024)
÷ (SalesQ2 2025
+ SalesQ1 2025
+ SalesQ4 2024
+ SalesQ3 2024)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The financial data reveals several notable trends in gross profit, sales, and gross profit margin over the periods under review.
- Sales Trend
- Sales exhibited a general upward trajectory from April 2020 to December 2022, rising from approximately $4,343 million to a peak near $8,369 million. However, starting in the first quarter of 2023, sales experienced a marked decline, dropping to around $5,749 million by mid-2025. This decline interrupted what had been a relatively steady growth pattern, indicating some volatility or external pressures affecting sales in the later periods.
- Gross Profit Trend
- Gross profit followed a somewhat parallel trend to sales initially, growing substantially from $2,443 million in early 2020 to nearly $4,939 million at the end of 2022. Post-2022, gross profit similarly declined, reaching around $3,523 million by mid-2025. This suggests that the reduction in gross profit closely aligns with the sales downturn, maintaining a consistent relationship between revenue and profitability at the gross level.
- Gross Profit Margin Analysis
- The gross profit margin, which started being reported from late 2020, demonstrated consistent stability and strength, fluctuating narrowly between approximately 55.98% and 60.95% during the period from late 2020 through the end of 2022. Even with the subsequent decrease in sales and gross profit from 2023 onwards, the margin held relatively steady, remaining in the upper 50% to low 60% range. This indicates effective cost management and pricing strategies that preserved profitability relative to sales, despite the volume declines.
- Overall Insights
- The data suggests that while the company experienced strong growth in both sales and gross profit throughout 2020 to 2022, there was a discernible downturn starting in 2023. Notwithstanding lower revenue and gross profit figures in recent periods, the stable gross profit margin underscores resilience in cost control and operational efficiency. The patterns may reflect changing market conditions or internal factors impacting sales volumes, yet the maintained margin provides a buffer mitigating impacts on profitability.
Operating Profit Margin
Jun 27, 2025 | Mar 28, 2025 | Dec 31, 2024 | Sep 27, 2024 | Jun 28, 2024 | Mar 29, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jul 1, 2022 | Apr 1, 2022 | Dec 31, 2021 | Oct 1, 2021 | Jul 2, 2021 | Apr 2, 2021 | Dec 31, 2020 | Oct 2, 2020 | Jul 3, 2020 | Apr 3, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||
Operating profit | |||||||||||||||||||||||||||||
Sales | |||||||||||||||||||||||||||||
Profitability Ratio | |||||||||||||||||||||||||||||
Operating profit margin1 | |||||||||||||||||||||||||||||
Benchmarks | |||||||||||||||||||||||||||||
Operating Profit Margin, Competitors2 | |||||||||||||||||||||||||||||
AbbVie Inc. | |||||||||||||||||||||||||||||
Amgen Inc. | |||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | |||||||||||||||||||||||||||||
Eli Lilly & Co. | |||||||||||||||||||||||||||||
Gilead Sciences Inc. | |||||||||||||||||||||||||||||
Johnson & Johnson | |||||||||||||||||||||||||||||
Merck & Co. Inc. | |||||||||||||||||||||||||||||
Pfizer Inc. | |||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-01), 10-Q (reporting date: 2021-07-02), 10-Q (reporting date: 2021-04-02), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-10-02), 10-Q (reporting date: 2020-07-03), 10-Q (reporting date: 2020-04-03).
1 Q2 2025 Calculation
Operating profit margin = 100
× (Operating profitQ2 2025
+ Operating profitQ1 2025
+ Operating profitQ4 2024
+ Operating profitQ3 2024)
÷ (SalesQ2 2025
+ SalesQ1 2025
+ SalesQ4 2024
+ SalesQ3 2024)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
- Operating Profit
- The operating profit figures demonstrate considerable volatility over the observed periods. Starting at 698 million USD in early April 2020, the operating profit rose steadily to a peak of 2,296 million USD at the end of 2022. However, from that peak, a downward trend is noticeable into 2023 and 2024, with operating profit declining to as low as 760 million USD by mid-2025. The fluctuations suggest periods of strong profitability followed by notable contractions.
- Sales
- Sales displayed an initial upward trajectory from 4,343 million USD in April 2020 to a high point of 8,369 million USD at the close of 2022. Subsequent quarters show a decline and stabilization at lower levels, with sales figures ranging mostly between 5,700 to 6,500 million USD from early 2023 through mid-2025. This indicates a reduction in sales volume or revenue generation post-2022, followed by a relatively stable but lower sales performance.
- Operating Profit Margin
- Operating profit margin data commences from the end of 2020, showing a healthy improvement and sustained high profitability margins through late 2022, ranging roughly between 22% and 27.6%. Margins peaked around 27.6% at the end of 2022 before gradually declining to below 20% by mid-2025. This decline in margin percentage points to increasing costs or pressures on profitability, despite a less pronounced fall in sales volumes.
- Overall Analysis
- The data reveals a period of strong growth and financial performance lasting until the end of 2022, characterized by rising sales and improving profitability margins. Following this peak period, both sales and operating profits decreased, with operating profit margins declining more sharply. The trends may imply challenges faced in maintaining growth or cost management in the latter periods, leading to a contraction in profitability and revenues. Continuous monitoring is advised to assess whether the recent declines represent cyclical adjustments or indicate longer-term issues affecting financial health.
Net Profit Margin
Jun 27, 2025 | Mar 28, 2025 | Dec 31, 2024 | Sep 27, 2024 | Jun 28, 2024 | Mar 29, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jul 1, 2022 | Apr 1, 2022 | Dec 31, 2021 | Oct 1, 2021 | Jul 2, 2021 | Apr 2, 2021 | Dec 31, 2020 | Oct 2, 2020 | Jul 3, 2020 | Apr 3, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||
Net earnings | |||||||||||||||||||||||||||||
Sales | |||||||||||||||||||||||||||||
Profitability Ratio | |||||||||||||||||||||||||||||
Net profit margin1 | |||||||||||||||||||||||||||||
Benchmarks | |||||||||||||||||||||||||||||
Net Profit Margin, Competitors2 | |||||||||||||||||||||||||||||
AbbVie Inc. | |||||||||||||||||||||||||||||
Amgen Inc. | |||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | |||||||||||||||||||||||||||||
Eli Lilly & Co. | |||||||||||||||||||||||||||||
Gilead Sciences Inc. | |||||||||||||||||||||||||||||
Johnson & Johnson | |||||||||||||||||||||||||||||
Merck & Co. Inc. | |||||||||||||||||||||||||||||
Pfizer Inc. | |||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-01), 10-Q (reporting date: 2021-07-02), 10-Q (reporting date: 2021-04-02), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-10-02), 10-Q (reporting date: 2020-07-03), 10-Q (reporting date: 2020-04-03).
1 Q2 2025 Calculation
Net profit margin = 100
× (Net earningsQ2 2025
+ Net earningsQ1 2025
+ Net earningsQ4 2024
+ Net earningsQ3 2024)
÷ (SalesQ2 2025
+ SalesQ1 2025
+ SalesQ4 2024
+ SalesQ3 2024)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The data reflects the quarterly financial performance over multiple periods with a focus on net earnings, sales, and net profit margin percentages.
- Net Earnings
- There is an overall fluctuating trend in net earnings across the quarters. Net earnings rose significantly from 595 million US$ in April 2020 to a peak of 1788 million US$ in December 2021. Following this peak, earnings exhibited a declining trend with occasional moderate recoveries, dropping sharply towards the end of the time series, reaching 555 million US$ in June 2025. This pattern indicates volatility in profitability with a notable peak period around late 2021.
- Sales
- Sales figures demonstrated a general upward trend from 4,343 million US$ in April 2020 to a peak of 8,369 million US$ in December 2022. Subsequently, sales declined, with some recovery attempts visible. By June 2025, sales stood at 5,936 million US$, substantially lower than the peak but still exceeding initial values. This suggests seasonal or cyclical factors affecting revenue generation, with the highest sales recorded at the end of 2022.
- Net Profit Margin
- Net profit margin data begins midway through the series, indicating margins starting at approximately 16.36% in December 2020, then increasing steadily to peak around 23.32% in March 2023. After this peak, margins progressively declined, falling to 14.21% by June 2025. This trajectory illustrates an improvement in operational efficiency or profit generation relative to sales until early 2023, followed by a tapering that might correlate with declining net earnings and sales levels.
In summary, the company experienced growth and strengthening profitability culminating near the end of 2021 through early 2023. After this period, a downward trend is observable in net earnings, sales, and profit margins, indicating potential challenges in maintaining profit levels and sales growth in the most recent quarters. The data suggests a need for further investigation into factors contributing to the recent declines.
Return on Equity (ROE)
Jun 27, 2025 | Mar 28, 2025 | Dec 31, 2024 | Sep 27, 2024 | Jun 28, 2024 | Mar 29, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jul 1, 2022 | Apr 1, 2022 | Dec 31, 2021 | Oct 1, 2021 | Jul 2, 2021 | Apr 2, 2021 | Dec 31, 2020 | Oct 2, 2020 | Jul 3, 2020 | Apr 3, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||
Net earnings | |||||||||||||||||||||||||||||
Total Danaher stockholders’ equity | |||||||||||||||||||||||||||||
Profitability Ratio | |||||||||||||||||||||||||||||
ROE1 | |||||||||||||||||||||||||||||
Benchmarks | |||||||||||||||||||||||||||||
ROE, Competitors2 | |||||||||||||||||||||||||||||
AbbVie Inc. | |||||||||||||||||||||||||||||
Amgen Inc. | |||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | |||||||||||||||||||||||||||||
Eli Lilly & Co. | |||||||||||||||||||||||||||||
Gilead Sciences Inc. | |||||||||||||||||||||||||||||
Johnson & Johnson | |||||||||||||||||||||||||||||
Merck & Co. Inc. | |||||||||||||||||||||||||||||
Pfizer Inc. | |||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-01), 10-Q (reporting date: 2021-07-02), 10-Q (reporting date: 2021-04-02), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-10-02), 10-Q (reporting date: 2020-07-03), 10-Q (reporting date: 2020-04-03).
1 Q2 2025 Calculation
ROE = 100
× (Net earningsQ2 2025
+ Net earningsQ1 2025
+ Net earningsQ4 2024
+ Net earningsQ3 2024)
÷ Total Danaher stockholders’ equity
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
The quarterly financial performance data reveals notable fluctuations in net earnings and a gradually increasing total stockholders’ equity over the observed periods. Return on equity (ROE) figures, available for certain quarters, provide insight into the company’s profitability relative to shareholder investment.
- Net Earnings
- Net earnings demonstrated significant variability over the course of the quarters. Starting from a relatively moderate level, earnings saw appreciable growth through to the early quarters of 2021, peaking around the Dec 31, 2020 and Jul 2, 2021 periods. Subsequently, net earnings experienced a decline throughout 2022 and entered a phase of lower performance during 2023 and 2024, with recurring fluctuations. The data for early 2025 indicates a further decrease, reaching the lowest levels within the timeline.
- Total Stockholders’ Equity
- The total stockholders’ equity exhibited a consistent upward trend from early 2020 through to the end of 2023, increasing incrementally each quarter. This steady growth suggests ongoing capital accumulation and reinvestment. Notably, there is a minor dip observed in mid-2024, but the equity base recovers and continues to rise towards mid-2025, maintaining an overall positive trajectory.
- Return on Equity (ROE)
- ROE values, available intermittently, show improved profitability in the earlier part of the timeline, peaking near mid to late 2021 at around 14%. Following this peak, ROE trends downward gradually through 2022 and 2023, falling below 10% in later periods. The decline continues into 2024 and early 2025, indicating reduced efficiency in generating returns from shareholders’ equity. This downward trend parallels the decreased net earnings during these quarters.
In summary, while the company’s equity base has expanded steadily, net earnings and ROE have experienced more volatility and a downward trend in recent periods. The financial data suggests challenges in maintaining profitability and return levels despite the growth in equity capitalization.
Return on Assets (ROA)
Jun 27, 2025 | Mar 28, 2025 | Dec 31, 2024 | Sep 27, 2024 | Jun 28, 2024 | Mar 29, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jul 1, 2022 | Apr 1, 2022 | Dec 31, 2021 | Oct 1, 2021 | Jul 2, 2021 | Apr 2, 2021 | Dec 31, 2020 | Oct 2, 2020 | Jul 3, 2020 | Apr 3, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||
Net earnings | |||||||||||||||||||||||||||||
Total assets | |||||||||||||||||||||||||||||
Profitability Ratio | |||||||||||||||||||||||||||||
ROA1 | |||||||||||||||||||||||||||||
Benchmarks | |||||||||||||||||||||||||||||
ROA, Competitors2 | |||||||||||||||||||||||||||||
AbbVie Inc. | |||||||||||||||||||||||||||||
Amgen Inc. | |||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | |||||||||||||||||||||||||||||
Eli Lilly & Co. | |||||||||||||||||||||||||||||
Gilead Sciences Inc. | |||||||||||||||||||||||||||||
Johnson & Johnson | |||||||||||||||||||||||||||||
Merck & Co. Inc. | |||||||||||||||||||||||||||||
Pfizer Inc. | |||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-01), 10-Q (reporting date: 2021-07-02), 10-Q (reporting date: 2021-04-02), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-10-02), 10-Q (reporting date: 2020-07-03), 10-Q (reporting date: 2020-04-03).
1 Q2 2025 Calculation
ROA = 100
× (Net earningsQ2 2025
+ Net earningsQ1 2025
+ Net earningsQ4 2024
+ Net earningsQ3 2024)
÷ Total assets
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
The financial data reveals several noteworthy trends over the periods analyzed. Net earnings exhibit considerable variability, with values peaking and troughing at various intervals. Notable high points in net earnings occurred in December 2020 (1,240 million US$), April 2021 (1,702 million US$), and December 2022 (2,232 million US$). However, after the peak in December 2022, net earnings show a declining trajectory, dropping to 555 million US$ by June 2025, indicating a significant decrease in profitability towards the latter periods.
Total assets demonstrate a generally stable to slightly fluctuating trend over the timeline. The asset base increased steadily from approximately 68,930 million US$ in early 2020 to about 84,350 million US$ by December 2022. Post this period, assets show moderate fluctuations, peaking around 87,734 million US$ in September 2023, before gradually declining to 81,620 million US$ by June 2025. This suggests a phase of asset consolidation or potential divestiture in the later periods.
Return on Assets (ROA) data, available from December 2020 onwards, initially shows a positive upward trend, starting at 4.79% and improving consistently to reach a peak of 8.55% by March 2023. This indicates increasing efficiency in asset utilization up to that point. However, from the peak onward, ROA declines steadily to 4.18% by June 2025, reflecting decreased profitability relative to asset size in the most recent periods.
- Net Earnings
- Marked by substantial volatility, with strong peaks near the end of 2020, early 2021, and late 2022, followed by a pronounced decline from early 2023 to mid-2025.
- Total Assets
- Show a general upward trend during 2020–2022, reaching a peak in late 2023, then moderate decline, indicative of asset base management changes or strategic shifts later on.
- Return on Assets (ROA)
- Initially improving through 2020–early 2023, peaking above 8%, followed by a downtrend to below 5% by mid-2025, highlighting a reduction in returns generated from assets over recent quarters.
In conclusion, the data suggests a phase of growth and improved profitability until early 2023, followed by a period of declining net earnings and asset efficiency. This pattern may warrant further investigation into underlying causes such as market conditions, operational challenges, or strategic adjustments impacting financial performance and asset utilization.